Skip to content

Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer

Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05220033
Enrollment
30
Registered
2022-02-02
Start date
2020-07-14
Completion date
2026-12-01
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gynecologic Cancer, Ovarian Cancer, Uterine Cancer

Brief summary

This study looks at how well the Journey Ahead intervention works in improving coping and communication skills in participants with gynecologic cancers.

Detailed description

Primary goals of this project are: Objective 1: Phase 1: To collect feedback from patients on CCI online and to assess patient's evaluation of CCI online. Objective 2: Phase 1: To examine the feasibility and acceptability of a CCI online. Objective 3: Phase 1/2: To collect preliminary data on changes in distress and coping associated with participation in CCI online.

Interventions

OTHERInformational intervention

Receive information focusing on coping skills for patients diagnosed with gynecologic cancer

OTHERsurvey administration

Ancillary studies

Sponsors

Rutgers, The State University of New Jersey
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with any stage of primary ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer or experienced a recurrence in the past 5 years; * Diagnosed with High Grade Stage 2, any grade Stage 3 or higher endometrial cancer or experienced a recurrence in the past 5 years; * Diagnosed with Stage 2 or higher cervical cancer or experienced a recurrence within the past 5 years; * Diagnosed with any stage Uterine Cancer (both Sarcoma and carcinosarcoma) or experienced a recurrence in the past 5 years; * At the time of recruitment the patient has received chemotherapy or radiation in the past 5 years, or is less than 5 years post-cancer surgery; * At the time of recruitment, a Karnofsky Performance Status of 80 or above or an Eastern Cooperative Oncology Group (ECOG) (80) score of 0 or 1; * 18 years of age or older; * English speaking; * Has internet access, able to view the online intervention sessions and attend telephone or video/telehealth chats to discuss the session content and provide feedback; * Must give informed consent within 5 years of diagnosis.

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Depressive symptoms change is being assessedBaseline, two and 6 months post-baselineDepressive symptoms will be measures with the Beck Depression inventory which is a 21-item scale which has been widely used in studies incorporating cognitive-behavioral interventions. Calculate score bye summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
Quality of life using the Fact-G change is being assessedBaseline, two and 6 months post-baselineThe Functional Assessment of Cancer Therapy - General (FACT-G) (110) is a widely used measure of QOL. The FACT-G is comprised of 27 questions that assess well-being in four domains: physical (PWB), functional (FWB), social/family (SFWB), and emotional (EWB). PWB assesses the physical symptoms; FWB assesses the degree to which the person can participate and enjoy normal daily activities; SFWB assesses social support and communication, and EWB measures mood and emotional response to illness. The domains are summed
Cancer specific distress change is being assessed over the time pointsBaseline, two and 6 months post-baselineThe Impact of Events Scale (IES) (108) is a 21-item self-report measure focusing on intrusive and avoidant ideation related to ovarian cancer and its treatment. Using a 4-point Likert scale, participants rate how true each statement has been for them during the past week (scale range = 0-75).
Psychological distress and well being change is being assessedBaseline, two and 6 months post-baselineThe MHI-18 has subscales for Psychological Distress (anxiety, depression and loss of behavioral and emotional control) and Well-being. can assess 4 subscales of emotional status like Anxiety, Depression, Behavioral control, and Positive affect. MHI generates one total score. The subscale and total scores range from 0 - 100, with higher scores indicate better mental health

Secondary

MeasureTime frameDescription
Emotional Acceptance scale ChangeBaseline, two and 6 months post-baselineThe Emotional Acceptance Scale (Stanton et. al., 2000) will be administered. Thirteen items include statements such as, I naturally and easily attend to my feelings, I allow myself to be in touch with my feelings because it is very good for me, and Knowing they are 'not perfect', I am comfortable with my feelings as they are. Participants indicate percentage of time they believe the statement is true for them ranging from 0 for never to 100 for almost always. The total score is the average for the 13 items (range 0 - 100) and higher scores indicate more emotional acceptance.
Physical impairmentBaseline, two and 6 months post-baselineThe 26 item Physical function scale of the CARES measure asks patients to rate physical limitations on a 5-point scale. The mean of all items is calculated.
Coping change is being assessedBaseline, two and 6 months post-baselineThe acceptance, positive reappraisal, and mental disengagement subscales of the COPE (Carver, Scheier, Weintraub 1989). The scale ranges from 1 = I usually don't do this at all 2 = I usually do this a little bit 3 = I usually do this a medium amount 4 = I usually do this a lot. The scale assess a broad range of coping responses
Positive emotional expressionBaseline, two and 6 months post-baselinePositive emotional expression is a 7 item subscale of the Emotional Expressiveness Questionnaire (King & Emmons, 1990). Items are rated on a 5-point Likert scale with 0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Frequently; 4 = Always. High scores ndicate a tendency to express emotion.
Holding back from sharing concernsBaseline, two and 6 months post-baselineThe degree to which the participant holds back from talking about cancer-related concerns with others will be measured by asking participants to rate how much each of 11 common cancer concerns is a concern and how much they hold back from talking to others about this concern. The Investigators adapted this scale from Porter and colleagues (Porter, et. al, 2005). A 13-item scale was used that measures the degree to which participants hold back from family and friends. Participants are asked to rate, on a 6-point scale, the degree to which they hold back from discussing issues of concern with friends and family. Scores are averaged to produce a total score, with higher scores indicating greater holding back
Unsupportive responses from friends and familyBaseline, two and 6 months post-baselineThe family and friend version of the perceived negative behavior scale (Manne, Pape, & Taylor, 1999) contains critical responses as well as more subtle responses of others. .Cronbach's alphas have ranged from .87 to .94 in the investigators' work with this patient population (Manne et al., 2019)
Psychological flexibilityBaseline, two and 6 months post-baselineThe 10-item Acceptance and Action Questionnaire-II will be used (AAQ-II) (Bond et. al., 2011) to assess avoidance and willingness to accept undesirable thoughts and feelings while acting in congruence with personal values and goals. a 1 = never true up to 7 = always true. Higher total scores mean less flexibility, while lower total scores mean more flexibility
HopeBaseline, two and 6 months post-baselineThe 6-item State Hope Scale (SHS; Snyder, Sympson, Ybasco, Borders, Babyak, & Higgins, 1996) measures agency (belief in one's ability to reach goals) and pathways (belief in one's ability to find routes to reach goals). Individuals rate how true or false each statement (e.g., I can think of many ways to reach my current goals.) is for them right now on a scale of 1 (Definitely false) to 8 (Definitely true). Total scores range from 6-48 and subscale scores range from 3-24.

Other

MeasureTime frameDescription
Medical outcome- cancer treatment historyBaseline, two and 6 months post-baselineChart reviews at baseline will capture cancer treatment history
Medical outcome- sleep disturbanceBaseline, two and 6 months post-baselineChart reviews at baseline will capture sleep disturbance
Medical Outcome- time since diagnosisBaseline, two and 6 months post-baselineChart reviews at baseline will capture time since diagnosis
Working alliance inventoryBaseline, two and 6 months post-baselineThe WAI Short Form (WAI-S) is a 12 item inventory rated on a 7-point Likert scale (A. O. Horvath, 1981, 2010). The measure has three alliance subscales: Bond, Task, and Goal.
Demographic informationBaseline onlyitems assessing age, education, ethnicity, occupation, employment status, income, religious affiliation, marital status and length of significant relationship (baseline only).
Medical information- type of cancerBaseline, two and 6 months post-baselineChart reviews at baseline will capture type of cancer
Medical Outcome- use of medication for pain, depression, anxietyBaseline, two and 6 months post-baselineChart reviews at baseline will capture use of medication for pain, depression, anxiety

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026